Payment overview · 2025
General Payments
$1,802.16
34 reported records · 12 companies
Healthcare provider profile · identity verified
Joshua D Cohen, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · MESA, AZ · NPI 1023066487
Verified facts
What the public records show
CMS Open Payments records show Joshua D Cohen, MD received $1,802.16 in general payments during 2025 across 34 reported records.
Medtronic, Inc. accounted for 56.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Wegovy.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Wegovy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$1,022.40 | 56.7% | 14 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $179.75 | 10.0% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $163.62 | 9.1% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $143.15 | 7.9% | 4 | 2025 |
| Koya Medical, Inc. | Unresolved — no canonical attribution shown | $61.57 | 3.4% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $55.82 | 3.1% | 3 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $54.44 | 3.0% | 3 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $32.21 | 1.8% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $29.84 | 1.7% | 2 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $27.96 | 1.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.55 | 0.9% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $14.85 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,181.83 | 26 |
| Travel and Lodging | $620.33 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $855.18 | 12 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $179.75 | 1 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $163.62 | 1 | 2025 |
Source payment records
|
|||||
| FFRANGIO Normalized: ffrangio |
Device | Medtronic, Inc. | $148.61 | 1 | 2025 |
Source payment records
|
|||||
| LUX-Dx Insertable Cardiac Monitor Normalized: lux dx insertable cardiac monitor |
Device | Boston Scientific Corporation | $112.50 | 1 | 2025 |
Source payment records
|
|||||
| DAYSPRING Normalized: dayspring |
Device | Koya Medical, Inc. | $61.57 | 1 | 2025 |
Source payment records
|
|||||
| KOYA MEDICAL Normalized: koya medical |
Device | Koya Medical, Inc. | $61.57 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $55.82 | 3 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $54.44 | 3 | 2025 |
Source payment records
|
|||||
| OPTOWIRE Normalized: optowire |
Device | CARDIVA MEDICAL, INC. | $32.21 | 2 | 2025 |
Source payment records
|
|||||
| Varithena Administration Pack Normalized: varithena administration pack |
Device | Boston Scientific Corporation | $30.65 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $29.84 | 2 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $27.96 | 1 | 2025 |
Source payment records
|
|||||
| VENASEAL Normalized: venaseal |
Device | Medtronic, Inc. | $18.61 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.55 | 1 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $14.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 167 | exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
167 | 59 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Succinate | Metoprolol Succinate | 1337 | 471 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1330 | 428 |
| Losartan Potassium | Losartan Potassium | 1073 | 349 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1047 | 346 |
| Amlodipine Besylate | Amlodipine Besylate | 1023 | 327 |
| Eliquis | Apixaban | 766 | 242 |
| Lisinopril | Lisinopril | 728 | 227 |
| Ezetimibe | Ezetimibe | 629 | 206 |
| Metoprolol Tartrate | Metoprolol Tartrate | 611 | 186 |
| Furosemide | Furosemide | 592 | 217 |
| Clopidogrel | Clopidogrel Bisulfate | 514 | 180 |
| Carvedilol | Carvedilol | 491 | 154 |
| Spironolactone | Spironolactone | 386 | 127 |
| Farxiga | Dapagliflozin Propanediol | 167 | 59 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 166 | 53 |
| Xarelto | Rivaroxaban | 166 | 52 |
| Warfarin Sodium | Warfarin Sodium | 165 | 62 |
| Entresto | Sacubitril/Valsartan | 154 | 46 |
| Amiodarone Hcl | Amiodarone Hcl | 152 | 59 |
| Simvastatin | Simvastatin | 124 | 41 |
| Sotalol | Sotalol Hcl | 122 | 47 |
| Atenolol | Atenolol | 119 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 117 | 40 |
| Hydralazine Hcl | Hydralazine Hcl | 111 | 37 |
| Valsartan | Valsartan | 111 | 39 |
| Pravastatin Sodium | Pravastatin Sodium | 107 | 37 |
| Potassium Chloride | Potassium Chloride | 98 | 35 |
| Chlorthalidone | Chlorthalidone | 96 | 33 |
| Ranolazine Er | Ranolazine | 95 | 29 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 87 | 29 |
| Midodrine Hcl | Midodrine Hcl | 82 | 35 |
| Flecainide Acetate | Flecainide Acetate | 76 | 24 |
| Repatha Sureclick | Evolocumab | 75 | 20 |
| Nebivolol Hcl | Nebivolol Hcl | 59 | 18 |
| Nitroglycerin | Nitroglycerin | 59 | 40 |
| Fenofibrate | Fenofibrate Nanocrystallized | 58 | 21 |
| Pantoprazole Sodium | Pantoprazole Sodium | 54 | 19 |
| Diltiazem 24hr Er | Diltiazem Hcl | 51 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 51 | 19 |
| Nifedipine Er | Nifedipine | 47 | 17 |
| Digoxin | Digoxin | 46 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 42 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | 12 |
| Ozempic | Semaglutide | 39 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 34 | suppressed |
| Metformin Hcl | Metformin Hcl | 32 | 15 |
| Bumetanide | Bumetanide | 31 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 29 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 29 | suppressed |
| Brilinta | Ticagrelor | 28 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 28 | 11 |
| Lovastatin | Lovastatin | 25 | suppressed |
| Cephalexin | Cephalexin | 24 | 23 |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Ramipril | Ramipril | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Clonidine | Clonidine | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 20 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 18 | suppressed |
| Gabapentin | Gabapentin | 18 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Praluent Pen | Alirocumab | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Wegovy | Semaglutide | 15 | suppressed |
| Famotidine | Famotidine | 14 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Omeprazole | Omeprazole | 13 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Multaq | Dronedarone Hcl | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,802.16 · 34 records | Medtronic, Inc. | Assure WCD, CARDIOMEMS, DAYSPRING, FARXIGA, FFRANGIO, FFRct, INSPIRE, KOYA MEDICAL, LUX-Dx Insertable Cardiac Monitor, LifeVest, OPTOWIRE, SAPIEN 3 Ultra RESILIA, SYMPLICITY G3, VENASEAL, Varithena Administration Pack, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error